



## Clinical trial results:

### A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults

#### Summary

EudraCT number	2020-005315-44
Trial protocol	DE IT HU PL BG
Global end of trial date	19 October 2022

#### Results information

Result version number	v2 (current)
This version publication date	02 August 2023
First version publication date	02 June 2023
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	D8851C00001
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04723394
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	S-151, Sodertalje, Sweden,
Public contact	Global Clinical Lead, AstraZeneca, 1 8772409479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca, 1 8772409479, information.center@astrazeneca.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 December 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	19 October 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To estimate the efficacy of AZD7442 in the prevention of the composite endpoint of either severe COVID-19 or death from any cause through study Day 29

Protection of trial subjects:

This study is conducted in accordance with the protocol and with the following: Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines; Applicable International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) Guidelines; Applicable laws and regulations. The protocol, protocol amendments, Informed Consent Form (ICF), Investigator Brochure, and other relevant documents (e.g. advertisements) must be submitted to an Institutional Review Board/Independent Ethics Committee (IRB/IEC) by the Investigator and reviewed and approved by the IRB/IEC before the study is initiated. Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients. Where applicable as per relevant laws and regulations, amendments will also be submitted to, reviewed and approved by regulatory authorities/national competent authorities.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 January 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 60
Country: Number of subjects enrolled	Brazil: 27
Country: Number of subjects enrolled	Czechia: 7
Country: Number of subjects enrolled	Germany: 92
Country: Number of subjects enrolled	Hungary: 3
Country: Number of subjects enrolled	Italy: 73
Country: Number of subjects enrolled	Japan: 42
Country: Number of subjects enrolled	Mexico: 310
Country: Number of subjects enrolled	Poland: 2
Country: Number of subjects enrolled	Russian Federation: 119
Country: Number of subjects enrolled	Spain: 70
Country: Number of subjects enrolled	Ukraine: 16
Country: Number of subjects enrolled	United Kingdom: 44
Country: Number of subjects enrolled	United States: 149

Worldwide total number of subjects	1014
EEA total number of subjects	247

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	890
From 65 to 84 years	123
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

910 participants were randomized to receive treatment in study D8851C00001 (TACKLE) with AZD7442 (AZD8895 + AZD1061) or placebo. Of the 910 participants randomized, 903 (99.2%) received treatment with study drug. Of the 903 dosed, 452 (50.1%) participants received AZD7442 and 451 (49.9%) participants received placebo.

### Pre-assignment

Screening details:

In TACKLE, at the first visit, ie, the enrollment visit 1, participants were evaluated regarding the protocol mandated inclusion and exclusion criteria. After enrolment, eligible participants were randomized at a 1: 1 ratio to receive a single dose of study provided AZD7442 (AZD8895 + AZD1061) or placebo.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	AZD7442

Arm description:

Single dose of 600 mg of AZD7442 (2 separate IM injections) on Day 1

Arm type	Experimental
Investigational medicinal product name	Combination of 2 mAbs (AZD8895 and AZD1061)
Investigational medicinal product code	
Other name	tixagevimab-cilgavimab
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose (× 2 separate IM injections) of 600 mg of AZD7442 on Day 1.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Single dose of Placebo (2 separate IM injections) on Day 1

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose (× 2 separate IM injections) of saline placebo on Day 1.

<b>Number of subjects in period 1<sup>[1]</sup></b>	AZD7442	Placebo
Started	452	451
Modified Full Analysis Set	413	421
Primary Analysis Population	410	419
Key Secondary Analysis Population	404 <sup>[2]</sup>	411
Completed	407	390
Not completed	45	61
Adverse event, serious fatal	8	8
Consent withdrawn by subject	17	33
Adverse event, non-fatal	-	3
Lost to follow-up	20	17

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: These participants are those who have non-missing results of key secondary endpoint.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: 1014 total participants enrolled in the study but only 903 dosed, and we report results of these dosed participants (Full Analysis Set).

## Baseline characteristics

### Reporting groups

Reporting group title	AZD7442
Reporting group description:	
Single dose of 600 mg of AZD7442 (2 separate IM injections) on Day 1	
Reporting group title	Placebo
Reporting group description:	
Single dose of Placebo (2 separate IM injections) on Day 1	

Reporting group values	AZD7442	Placebo	Total
Number of subjects	452	451	903
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	393	394	787
From 65-84 years	59	56	115
85 years and over	0	1	1
Age Continuous			
Full Analysis Set			
Units: years			
median	46.0	46.0	
full range (min-max)	18.0 to 83.0	18.0 to 86.0	-
Sex: Female, Male			
Units: Participants			
Female	239	216	455
Male	213	235	448
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	230	238	468
Not Hispanic or Latino	222	213	435
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	100	115	215
Asian	30	21	51
Black or African American	16	20	36
Multiple	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Not reported	21	21	42
White	285	274	559
Risk of Progression to Severe COVID-19			
Risk of Progression to Severe COVID-19 is assessed based on participant's medical history - based on			

FDA/CDC guidelines. Summarized in the Full Analysis Set			
Units: Subjects			
High	405	406	811
Low	47	45	92
Country			
Units: Subjects			
Argentina	29	28	57
Brazil	7	12	19
Czech Republic	3	2	5
Germany	33	38	71
Hungary	2	1	3
Italy	37	33	70
Japan	26	14	40
Mexico	139	166	305
Poland	1	1	2
Russian Federation	55	51	106
Spain	31	37	68
Ukraine	5	10	15
United Kingdom	20	18	38
United States	64	40	104
BMI (kg/m <sup>2</sup> )			
Full Analysis Set			
Units: kg/m <sup>2</sup>			
arithmetic mean	28.9	29.2	
standard deviation	± 5.46	± 6.56	-
Age Continuous			
Full Analysis Set			
Units: Years			
arithmetic mean	46.3	45.9	
standard deviation	± 15.42	± 14.99	-

### Subject analysis sets

Subject analysis set title	AZD7442 modified Full Analysis Set
Subject analysis set type	Full analysis

Subject analysis set description:

All participants in the full analysis set who received AZD7442 ≤ 7 days from symptom onset and were not hospitalized at baseline (≤ Day 1) for isolation purpose.

Subject analysis set title	Placebo modified Full Analysis Set
Subject analysis set type	Full analysis

Subject analysis set description:

All participants in the full analysis set who received placebo ≤ 7 days from symptom onset and were not hospitalized at baseline (≤ Day 1) for isolation purpose.

Reporting group values	AZD7442 modified Full Analysis Set	Placebo modified Full Analysis Set	
Number of subjects	413	421	
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			

Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age Continuous			
Full Analysis Set			
Units: years median full range (min-max)			
Sex: Female, Male			
Units: Participants			
Female	226	206	
Male	187	215	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino Not Hispanic or Latino			
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native Asian Black or African American Multiple Native Hawaiian or Other Pacific Islander Not reported White			
Risk of Progression to Severe COVID-19			
Risk of Progression to Severe COVID-19 is assessed based on participant's medical history - based on FDA/CDC guidelines. Summarized in the Full Analysis Set			
Units: Subjects			
High Low			
Country			
Units: Subjects			
Argentina Brazil Czech Republic Germany Hungary Italy Japan Mexico Poland Russian Federation Spain Ukraine United Kingdom United States			



BMI (kg/m <sup>2</sup> )			
Full Analysis Set			
Units: kg/m <sup>2</sup>			
arithmetic mean			
standard deviation	±	±	
Age Continuous			
Full Analysis Set			
Units: Years			
arithmetic mean			
standard deviation	±	±	

## End points

### End points reporting groups

Reporting group title	AZD7442
Reporting group description:	
Single dose of 600 mg of AZD7442 (2 separate IM injections) on Day 1	
Reporting group title	Placebo
Reporting group description:	
Single dose of Placebo (2 separate IM injections) on Day 1	
Subject analysis set title	AZD7442 modified Full Analysis Set
Subject analysis set type	Full analysis
Subject analysis set description:	
All participants in the full analysis set who received AZD7442 $\leq 7$ days from symptom onset and were not hospitalized at baseline ( $\leq$ Day 1) for isolation purpose.	
Subject analysis set title	Placebo modified Full Analysis Set
Subject analysis set type	Full analysis
Subject analysis set description:	
All participants in the full analysis set who received placebo $\leq 7$ days from symptom onset and were not hospitalized at baseline ( $\leq$ Day 1) for isolation purpose.	

### Primary: A Composite of Either Severe COVID-19 or Death From Any Cause Through Day 29

End point title	A Composite of Either Severe COVID-19 or Death From Any Cause Through Day 29
End point description:	
Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypnea, or dyspnea, and lung infiltrates) or hypoxemia ( $\text{SpO}_2 < 90\%$ in room air and/or severe respiratory distress) and a WHO Clinical Progression Scale score of 5 or higher.	
End point type	Primary
End point timeframe:	
Baseline (Day 1) and Day 29	

End point values	AZD7442 modified Full Analysis Set	Placebo modified Full Analysis Set		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	410	419		
Units: Participants	18	37		

### Statistical analyses

Statistical analysis title	relative risk reduction
Statistical analysis description:	
AZD7442 vs Placebo	
Comparison groups	AZD7442 modified Full Analysis Set v Placebo modified Full Analysis Set

Number of subjects included in analysis	829
Analysis specification	Pre-specified
Analysis type	superiority <sup>[1]</sup>
P-value	= 0.01
Method	Cochran-Mantel-Haenszel
Parameter estimate	Relative Risk Reduction (100*[1-RR])
Point estimate	50.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.38
upper limit	71.25

Notes:

[1] - The relative risk reduction RRR represents the percent reduction in incidence of severe COVID-19 or death from any cause in the AZD7442 group relative to placebo. A RRR > 0 represents favorable efficacy in the AZD7442 group. A p-value <0.05 indicates a statistically significant result.

### Secondary: A Composite of Death From Any Cause or Hospitalization for COVID-19 Complications or Sequelae Through Day 169

End point title	A Composite of Death From Any Cause or Hospitalization for COVID-19 Complications or Sequelae Through Day 169
End point description:	
Death from Any Cause or Hospitalization for COVID-19 Complications or Sequelae through Day 169	
End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Day 169	

End point values	AZD7442 modified Full Analysis Set	Placebo modified Full Analysis Set		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	404	411		
Units: Participants	20	40		

### Statistical analyses

Statistical analysis title	relative risk reduction
Statistical analysis description:	
AZD7442 vs Placebo	
Comparison groups	AZD7442 modified Full Analysis Set v Placebo modified Full Analysis Set
Number of subjects included in analysis	815
Analysis specification	Pre-specified
Analysis type	superiority <sup>[2]</sup>
P-value	= 0.009
Method	Cochran-Mantel-Haenszel
Parameter estimate	Relative Risk Reduction (100*[1-RR])
Point estimate	49.24

Confidence interval	
level	95 %
sides	2-sided
lower limit	14.72
upper limit	69.79

Notes:

[2] - The relative risk reduction RRR represents the percent reduction in incidence of death from any cause or hospitalization for COVID-19 complications or sequelae in the AZD7442 group relative to placebo. A RRR > 0 represents favorable efficacy in the AZD7442 group. A p-value <0.05 indicates a statistically significant result. Participants who discontinued or were lost to follow up prior to Day 169 are considered missing.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug until end of study, with an average of 436 days.

Adverse event reporting additional description:

AEs are reported for the Safety Analysis Set, defined as all participants randomized and dosed with IMP.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Single dose of Placebo (2 separate IM injections) on Day 1

Reporting group title	AZD7442
-----------------------	---------

Reporting group description:

Single dose of 600 mg of AZD7442 (2 separate IM injections) on Day 1

Serious adverse events	Placebo	AZD7442	
Total subjects affected by serious adverse events			
subjects affected / exposed	65 / 451 (14.41%)	46 / 452 (10.18%)	
number of deaths (all causes)	8	8	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Gastric cancer			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Colorectal cancer metastatic			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vascular disorders			
Hypertensive emergency			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			

subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Sudden cardiac death			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Death			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Reproductive system and breast disorders			
Adenomyosis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			

subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Bipolar disorder			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disorientation			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Forearm fracture			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in gastrointestinal tract			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw fracture			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Road traffic accident			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute myocardial infarction			
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Arrhythmia			
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute coronary syndrome			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular extrasystoles			



subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Loss of consciousness			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Optic neuritis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior sagittal sinus thrombosis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia of malignant disease			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Blood loss anaemia			

subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Diabetic retinopathy			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Oesophageal varices haemorrhage			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Portal vein thrombosis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric obstruction			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immobilisation syndrome			

subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia bacterial			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superinfection bacterial			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sinusitis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial diarrhoea			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	9 / 451 (2.00%)	2 / 452 (0.44%)	
occurrences causally related to treatment / all	0 / 9	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
COVID-19 pneumonia			
subjects affected / exposed	37 / 451 (8.20%)	23 / 452 (5.09%)	
occurrences causally related to treatment / all	0 / 37	0 / 23	
deaths causally related to treatment / all	0 / 5	0 / 2	
Cellulitis			

subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated tuberculosis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sepsis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomonas infection			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-acute COVID-19 syndrome			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Placebo	AZD7442	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	224 / 451 (49.67%)	230 / 452 (50.88%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Plasma cell myeloma			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Bladder cancer			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Anogenital warts			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Acrochordon			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Seborrhoeic keratosis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Uterine leiomyoma			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
Aortic arteriosclerosis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Brachiocephalic arteriosclerosis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Deep vein thrombosis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Essential hypertension			

subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Hot flush			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Hypertension			
subjects affected / exposed	18 / 451 (3.99%)	16 / 452 (3.54%)	
occurrences (all)	18	16	
Hypertensive crisis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Hypertensive urgency			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Hypotension			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Lymphostasis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Peripheral artery aneurysm			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Thrombophlebitis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Venous thrombosis limb			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Surgical and medical procedures			
Abdominal wall operation			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
General disorders and administration site conditions			

Asthenia		
subjects affected / exposed	9 / 451 (2.00%)	8 / 452 (1.77%)
occurrences (all)	9	10
Chest discomfort		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Decreased activity		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Energy increased		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	2	1
Injection site haematoma		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Fatigue		
subjects affected / exposed	15 / 451 (3.33%)	16 / 452 (3.54%)
occurrences (all)	17	16
Feeling hot		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Gait disturbance		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Injection site bruising		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Injection site erythema		
subjects affected / exposed	2 / 451 (0.44%)	2 / 452 (0.44%)
occurrences (all)	2	2
Face oedema		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Injection site induration		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1



Injection site nodule		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	2
Injection site pain		
subjects affected / exposed	11 / 451 (2.44%)	8 / 452 (1.77%)
occurrences (all)	15	12
Injection site swelling		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	2
Injection site warmth		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	2	0
Malaise		
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)
occurrences (all)	1	2
Pain		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Pyrexia		
subjects affected / exposed	0 / 451 (0.00%)	3 / 452 (0.66%)
occurrences (all)	0	4
Suprapubic pain		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Vaccination site pain		
subjects affected / exposed	2 / 451 (0.44%)	3 / 452 (0.66%)
occurrences (all)	3	6
Vaccination site reaction		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Injection site inflammation		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Influenza like illness		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1

Adverse drug reaction subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	1 / 452 (0.22%) 1	
Application site haematoma subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Oedema peripheral subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	0 / 452 (0.00%) 0	
Non-cardiac chest pain subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	1 / 452 (0.22%) 1	
Injection site discomfort subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	2 / 452 (0.44%) 3	
Immune system disorders Allergy to arthropod sting subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	2 / 452 (0.44%) 2	
Drug hypersensitivity subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 2	0 / 452 (0.00%) 0	
Social circumstances Unhealthy diet subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Reproductive system and breast disorders Bartholin's cyst subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	

Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	1 / 452 (0.22%) 1
Breast discharge subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1
Endometrial thickening subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0
Erectile dysfunction subjects affected / exposed occurrences (all)	4 / 451 (0.89%) 4	0 / 452 (0.00%) 0
Hypomenorrhoea subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0
Menopausal symptoms subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	1 / 452 (0.22%) 1
Menstruation irregular subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1
Nipple pain subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1
Ovarian cyst subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0
Polycystic ovaries subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1
Prostatitis subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	1 / 452 (0.22%) 1
Prostatomegaly subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0

Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Vulvovaginal erythema subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Organising pneumonia subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Asthma subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	2 / 452 (0.44%) 2	
Bronchial hyperreactivity subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Bronchitis chronic subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Bronchospasm subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	1 / 452 (0.22%) 1	
Cough subjects affected / exposed occurrences (all)	4 / 451 (0.89%) 4	8 / 452 (1.77%) 8	
Dyspnoea subjects affected / exposed occurrences (all)	11 / 451 (2.44%) 12	3 / 452 (0.66%) 3	
Dyspnoea exertional			

subjects affected / exposed	3 / 451 (0.67%)	4 / 452 (0.88%)
occurrences (all)	3	5
Epistaxis		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	4	0
Hiccups		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Interstitial lung disease		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	2
Nasal congestion		
subjects affected / exposed	3 / 451 (0.67%)	1 / 452 (0.22%)
occurrences (all)	3	1
Nasal obstruction		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Oropharyngeal pain		
subjects affected / exposed	3 / 451 (0.67%)	0 / 452 (0.00%)
occurrences (all)	4	0
Pleurisy		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Productive cough		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Pulmonary fibrosis		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Rales		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Respiratory failure		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Rhinitis allergic		

subjects affected / exposed occurrences (all)	3 / 451 (0.67%) 3	1 / 452 (0.22%) 1	
Rhinorrhoea			
subjects affected / exposed occurrences (all)	4 / 451 (0.89%) 5	0 / 452 (0.00%) 0	
Sleep apnoea syndrome			
subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Throat irritation			
subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Vocal cord polyp			
subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Wheezing			
subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Psychiatric disorders			
Alcohol abuse			
subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Alcoholism			
subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Anxiety			
subjects affected / exposed occurrences (all)	4 / 451 (0.89%) 4	3 / 452 (0.66%) 3	
Anxiety disorder			
subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Attention deficit hyperactivity disorder			
subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Bruxism			

subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Burnout syndrome			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Confusional state			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	2	1	
Depression			
subjects affected / exposed	5 / 451 (1.11%)	5 / 452 (1.11%)	
occurrences (all)	5	5	
Insomnia			
subjects affected / exposed	2 / 451 (0.44%)	7 / 452 (1.55%)	
occurrences (all)	2	7	
Mixed anxiety and depressive disorder			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Sleep disorder			
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)	
occurrences (all)	1	2	
Stress			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Acute stress disorder			
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)	
occurrences (all)	2	0	
Hepatobiliary disorders			
Non-alcoholic steatohepatitis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Biliary colic			
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)	
occurrences (all)	1	2	
Cholecystitis			

subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Cholecystitis chronic			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Cholelithiasis			
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)	
occurrences (all)	0	2	
Cholestasis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Drug-induced liver injury			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Hepatic failure			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Hepatic steatosis			
subjects affected / exposed	2 / 451 (0.44%)	2 / 452 (0.44%)	
occurrences (all)	2	2	
Hepatitis toxic			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Blood urine present			



subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Body temperature increased		
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)
occurrences (all)	0	2
Cardiac murmur		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
White blood cell count decreased		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Transaminases increased		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Platelet count increased		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Oxygen saturation decreased		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	2	1
Neutrophil count decreased		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Lipids abnormal		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Hepatitis A antibody		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Hepatic enzyme increased		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
C-reactive protein increased		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Aspartate aminotransferase		

increased			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
Post-traumatic neck syndrome			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Post procedural swelling			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Anaemia postoperative			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Ankle fracture			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Complications of transplanted kidney			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Contusion			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Head injury			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Incision site haemorrhage			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Joint injury			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Ligament injury			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Ligament sprain			

subjects affected / exposed	5 / 451 (1.11%)	1 / 452 (0.22%)	
occurrences (all)	5	1	
Limb injury			
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)	
occurrences (all)	2	0	
Meniscus injury			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Muscle injury			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Muscle strain			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Post-traumatic pain			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Road traffic accident			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Skin abrasion			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Thermal burn			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Vaccination complication			
subjects affected / exposed	13 / 451 (2.88%)	13 / 452 (2.88%)	
occurrences (all)	33	29	
Procedural haemorrhage			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Fall			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Congenital, familial and genetic			

disorders			
Azygos lobe			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Atrial fibrillation			
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)	
occurrences (all)	2	1	
Atrioventricular block first degree			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Bradycardia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Cardiac failure acute			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Cardiac failure chronic			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Cardiac flutter			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Coronary artery disease			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Mitral valve disease			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Myocardial ischaemia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	2	0	
Nodal rhythm			

subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Palpitations			
subjects affected / exposed	2 / 451 (0.44%)	3 / 452 (0.66%)	
occurrences (all)	2	3	
Sinus arrhythmia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Sinus bradycardia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Sinus tachycardia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Ventricular extrasystoles			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Lumbar radiculopathy			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Loss of consciousness			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Intercostal neuralgia			
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)	
occurrences (all)	2	0	
Hyposmia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Hypoaesthesia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Hypersomnia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	

Hypergeusia		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Hemiparaesthesia		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Headache		
subjects affected / exposed	11 / 451 (2.44%)	13 / 452 (2.88%)
occurrences (all)	15	14
Head discomfort		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Facial paralysis		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Encephalopathy		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Dysgeusia		
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)
occurrences (all)	1	2
Dysaesthesia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Dizziness		
subjects affected / exposed	1 / 451 (0.22%)	8 / 452 (1.77%)
occurrences (all)	1	8
Disturbance in attention		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	2	1
Cervicobrachial syndrome		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Cerebrovascular disorder		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1

Cerebral hypoperfusion		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Cerebral arteriosclerosis		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Carpal tunnel syndrome		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Aphasia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Apallic syndrome		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Anosmia		
subjects affected / exposed	3 / 451 (0.67%)	8 / 452 (1.77%)
occurrences (all)	3	9
Amnesia		
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)
occurrences (all)	1	2
Ageusia		
subjects affected / exposed	2 / 451 (0.44%)	2 / 452 (0.44%)
occurrences (all)	2	2
Memory impairment		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	2	0
Migraine		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Neuralgia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Paraesthesia		
subjects affected / exposed	4 / 451 (0.89%)	0 / 452 (0.00%)
occurrences (all)	4	0

Parosmia			
subjects affected / exposed	3 / 451 (0.67%)	2 / 452 (0.44%)	
occurrences (all)	3	2	
Restless legs syndrome			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Syncope			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Tarsal tunnel syndrome			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Taste disorder			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Blood and lymphatic system disorders			
Normochromic normocytic anaemia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Anaemia			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Bicytopenia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Anaemia of malignant disease			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Iron deficiency anaemia			
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)	
occurrences (all)	2	1	
Nephrogenic anaemia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Lymphadenopathy			



subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	1 / 452 (0.22%) 1	
Leukopenia subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Thrombocytosis subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	1 / 452 (0.22%) 1	
Ear and labyrinth disorders Deafness subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Ear pain subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Vertigo subjects affected / exposed occurrences (all)	3 / 451 (0.67%) 3	1 / 452 (0.22%) 1	
Vertigo positional subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Eye disorders Cataract subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Conjunctivitis allergic subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	1 / 452 (0.22%) 1	
Diabetic retinal oedema			

subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Diabetic retinopathy			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Diplopia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Eyelid oedema			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Glaucoma			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Ocular hyperaemia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Retinal detachment			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Visual impairment			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Conjunctival disorder			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Abdominal pain			
subjects affected / exposed	3 / 451 (0.67%)	2 / 452 (0.44%)	
occurrences (all)	3	2	
Abdominal pain lower			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	

Abdominal pain upper subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	2 / 452 (0.44%) 2
Anal fissure subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0
Anal pruritus subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1
Chronic gastritis subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	2 / 452 (0.44%) 2
Coeliac disease subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0
Colitis ulcerative subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1
Constipation subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	4 / 452 (0.88%) 4
Diarrhoea subjects affected / exposed occurrences (all)	6 / 451 (1.33%) 6	11 / 452 (2.43%) 12
Diverticulum intestinal subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1
Toothache subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	0 / 452 (0.00%) 0
Reflux gastritis subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1

Pancreatitis chronic		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Oesophagitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Oesophageal spasm		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0
Nausea		
subjects affected / exposed	3 / 451 (0.67%)	5 / 452 (1.11%)
occurrences (all)	3	5
Irritable bowel syndrome		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0
Intra-abdominal haematoma		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Hiatus hernia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Haemorrhoids		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	2	1
Haematochezia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Gastrooesophageal reflux disease		
subjects affected / exposed	4 / 451 (0.89%)	3 / 452 (0.66%)
occurrences (all)	4	3
Gastrointestinal haemorrhage		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Gastrointestinal disorder		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1

Gastritis			
subjects affected / exposed	4 / 451 (0.89%)	3 / 452 (0.66%)	
occurrences (all)	5	3	
Functional gastrointestinal disorder			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Food poisoning			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Flatulence			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Duodenitis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Diverticulum oesophageal			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Stomatitis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Dyspepsia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Glossodynia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Inguinal hernia			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Odynophagia			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Dermatitis allergic			

subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
<b>Dermatitis</b>		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0
<b>Drug eruption</b>		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
<b>Dry skin</b>		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
<b>Eczema</b>		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
<b>Erythema</b>		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
<b>Hyperhidrosis</b>		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
<b>Macule</b>		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
<b>Neurodermatitis</b>		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
<b>Prurigo</b>		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	2	0
<b>Pruritus</b>		
subjects affected / exposed	4 / 451 (0.89%)	3 / 452 (0.66%)
occurrences (all)	4	3
<b>Psoriasis</b>		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
<b>Rash</b>		

subjects affected / exposed occurrences (all)	4 / 451 (0.89%) 4	4 / 452 (0.88%) 4	
Alopecia subjects affected / exposed occurrences (all)	7 / 451 (1.55%) 8	5 / 452 (1.11%) 5	
Blister subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	1 / 452 (0.22%) 1	
Decubitus ulcer subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	1 / 452 (0.22%) 1	
Dermatitis contact subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Rash pruritic subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Skin ulcer subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Urticaria subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Xeroderma subjects affected / exposed occurrences (all)	1 / 451 (0.22%) 1	0 / 452 (0.00%) 0	
Skin reaction subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	
Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all)	2 / 451 (0.44%) 2	1 / 452 (0.22%) 1	
Dysuria subjects affected / exposed occurrences (all)	0 / 451 (0.00%) 0	1 / 452 (0.22%) 1	

Haematuria			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Oliguria			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Pollakiuria			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Hyperthyroidism			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Hypothyroidism			
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)	
occurrences (all)	0	2	
Thyroid mass			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	8 / 451 (1.77%)	9 / 452 (1.99%)	
occurrences (all)	8	10	
Arthritis			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Arthritis enteropathic			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Arthropathy			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Back pain			



subjects affected / exposed	10 / 451 (2.22%)	10 / 452 (2.21%)
occurrences (all)	10	11
Costochondritis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Fibromyalgia		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0
Intervertebral disc protrusion		
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)
occurrences (all)	1	2
Tendonitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Tendon pain		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Synovitis		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Spinal osteoarthritis		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Sjogren's syndrome		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Rhabdomyolysis		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Plantar fasciitis		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Pain in extremity		
subjects affected / exposed	3 / 451 (0.67%)	1 / 452 (0.22%)
occurrences (all)	4	1
Osteoporosis		

subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)	
occurrences (all)	0	2	
Osteochondrosis			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Osteoarthritis			
subjects affected / exposed	1 / 451 (0.22%)	3 / 452 (0.66%)	
occurrences (all)	2	3	
Neck pain			
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)	
occurrences (all)	0	2	
Myositis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Myalgia			
subjects affected / exposed	4 / 451 (0.89%)	7 / 452 (1.55%)	
occurrences (all)	5	7	
Musculoskeletal discomfort			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Musculoskeletal chest pain			
subjects affected / exposed	2 / 451 (0.44%)	3 / 452 (0.66%)	
occurrences (all)	2	3	
Muscle spasms			
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)	
occurrences (all)	1	2	
Muscle contracture			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Mastication disorder			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Joint stiffness			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Infections and infestations			

Gastroenteritis viral		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Acute sinusitis		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	2
Asymptomatic COVID-19		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Bed bug infestation		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Bronchiolitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Bronchitis		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	2	1
Bronchitis bacterial		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Bronchitis viral		
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)
occurrences (all)	0	2
COVID-19		
subjects affected / exposed	43 / 451 (9.53%)	49 / 452 (10.84%)
occurrences (all)	44	49
COVID-19 pneumonia		
subjects affected / exposed	12 / 451 (2.66%)	4 / 452 (0.88%)
occurrences (all)	12	4
Cellulitis		
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)
occurrences (all)	0	2
Cervicitis		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1

Chlamydial infection		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0
Clostridium difficile colitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Conjunctivitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Cystitis		
subjects affected / exposed	2 / 451 (0.44%)	2 / 452 (0.44%)
occurrences (all)	2	2
Diarrhoea infectious		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Ear infection		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Enterobacter pneumonia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Epididymitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Fungal skin infection		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Furuncle		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Gastroenteritis		
subjects affected / exposed	2 / 451 (0.44%)	6 / 452 (1.33%)
occurrences (all)	2	6
Gingivitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0

Sinusitis bacterial		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Gonorrhoea		
subjects affected / exposed	3 / 451 (0.67%)	0 / 452 (0.00%)
occurrences (all)	3	0
H3N2 influenza		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Helicobacter gastritis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Helicobacter infection		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0
Herpes zoster		
subjects affected / exposed	0 / 451 (0.00%)	4 / 452 (0.88%)
occurrences (all)	0	4
Influenza		
subjects affected / exposed	2 / 451 (0.44%)	4 / 452 (0.88%)
occurrences (all)	3	5
Lower respiratory tract infection		
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)
occurrences (all)	0	2
Mastitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Nasopharyngitis		
subjects affected / exposed	8 / 451 (1.77%)	4 / 452 (0.88%)
occurrences (all)	10	4
Onychomycosis		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Otitis externa		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	2

Otitis media		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Pharyngitis		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0
Pharyngotonsillitis		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	3	1
Pneumonia bacterial		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	2	1
Post-acute COVID-19 syndrome		
subjects affected / exposed	29 / 451 (6.43%)	38 / 452 (8.41%)
occurrences (all)	30	39
Pyelonephritis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Pyelonephritis chronic		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Respiratory tract infection		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Respiratory tract infection viral		
subjects affected / exposed	3 / 451 (0.67%)	1 / 452 (0.22%)
occurrences (all)	3	1
Gonococcal infection		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Tinea pedis		
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)
occurrences (all)	0	2
Tonsillitis		
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)
occurrences (all)	1	2

Tooth infection		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Upper respiratory tract infection		
subjects affected / exposed	4 / 451 (0.89%)	4 / 452 (0.88%)
occurrences (all)	4	4
Upper respiratory tract infection bacterial		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Urinary tract infection		
subjects affected / exposed	9 / 451 (2.00%)	10 / 452 (2.21%)
occurrences (all)	11	11
Vaginal infection		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Vestibular neuronitis		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Viral infection		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Viral rhinitis		
subjects affected / exposed	1 / 451 (0.22%)	2 / 452 (0.44%)
occurrences (all)	1	2
Viral upper respiratory tract infection		
subjects affected / exposed	0 / 451 (0.00%)	3 / 452 (0.66%)
occurrences (all)	0	3
Vulvovaginal candidiasis		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	2	1
Suspected COVID-19		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Syphilis		

subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Sinusitis			
subjects affected / exposed	5 / 451 (1.11%)	1 / 452 (0.22%)	
occurrences (all)	7	1	
Pneumonia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Periodontitis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Oral herpes			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Genitourinary chlamydia infection			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	
Chronic sinusitis			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	2	0	
Metabolism and nutrition disorders			
Glucose tolerance impaired			
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)	
occurrences (all)	1	1	
Dyslipidaemia			
subjects affected / exposed	5 / 451 (1.11%)	3 / 452 (0.66%)	
occurrences (all)	5	3	
Diabetes mellitus inadequate control			
subjects affected / exposed	4 / 451 (0.89%)	7 / 452 (1.55%)	
occurrences (all)	5	10	
Diabetes mellitus			
subjects affected / exposed	3 / 451 (0.67%)	2 / 452 (0.44%)	
occurrences (all)	3	2	
Dehydration			
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)	
occurrences (all)	0	1	



Gout		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Hypocalcaemia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Hypokalaemia		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Type 2 diabetes mellitus		
subjects affected / exposed	7 / 451 (1.55%)	9 / 452 (1.99%)
occurrences (all)	7	9
Vitamin B12 deficiency		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Vitamin D deficiency		
subjects affected / exposed	2 / 451 (0.44%)	1 / 452 (0.22%)
occurrences (all)	2	1
Weight gain poor		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Hypercholesterolaemia		
subjects affected / exposed	0 / 451 (0.00%)	1 / 452 (0.22%)
occurrences (all)	0	1
Hyperglycaemia		
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)
occurrences (all)	1	0
Hyperkalaemia		
subjects affected / exposed	1 / 451 (0.22%)	1 / 452 (0.22%)
occurrences (all)	1	1
Hyperlipidaemia		
subjects affected / exposed	0 / 451 (0.00%)	2 / 452 (0.44%)
occurrences (all)	0	2
Hypernatraemia		
subjects affected / exposed	2 / 451 (0.44%)	0 / 452 (0.00%)
occurrences (all)	2	0

Hypertriglyceridaemia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	
Hyperuricaemia			
subjects affected / exposed	1 / 451 (0.22%)	0 / 452 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 December 2020	Update to the key secondary objective and associated analysis estimand to include as intercurrent events, participants who are unblinded to be considered for COVID-19 vaccination. Consequential consistency change to Section 9.4.2.1 (Primary Endpoint).
26 February 2021	COVID places pregnant women at increased risk of poor outcomes and poor pregnancy outcomes (CDC, 2021). A fetal TCR study showed no binding of AZD7442 mAbs to any fetal tissues tested. Prior experience with antibody therapy against infectious diseases and with other mAbs suggests low risk in pregnancy. Therefore, the exclusion of pregnant or breast feeding women has been removed from the CSP.
10 March 2021	Pregnant women and breastfeeding mothers are excluded from the trial (Criterion 16) as there is insufficient data on the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes or effects of the drug on the breastfed infant, or on milk production. All women of child bearing potential must have a negative pregnancy test result at Visit 1 (Criterion 8b). AstraZeneca acknowledges the risk for severe COVID-19 in pregnant women but would like to establish the risk/benefit profile in adults before including pregnant women in the clinical trial.
31 March 2021	Highly efficacious vaccines against SARS-CoV-2 are being deployed on a mass scale in the participating countries, leading to substantially decreasing attack rates for COVID-19 and reduced potential for study enrollment. Therefore, the interim analysis has been removed and the primary analysis adjusted so that it is completed 30 days after the 52nd event has occurred. This period, of 30 days, allows sufficient time for the 52nd event to be monitored, and any other events occurring during this time interval will also be evaluated. Enrollment will stop after the 52nd event has occurred.
21 April 2021	Amid a rising number of coronavirus disease 2019 (COVID-19) hospitalizations across the world, leading to a shortage of hospital beds, temporary facilities are being utilized increasingly to manage severe COVID-19 patients who would have usually been treated in a traditional hospital setting. As hospitalizations are an integral component of both the primary and key secondary endpoints in the study, further guidance is provided regarding what constitutes these temporary facility or alternate care sites used for managing participants with severe COVID-19.
05 July 2021	Due to regional differences in medical practice for COVID-19, the primary analysis population has been clarified to ensure that the efficacy of AZD7442 for the treatment of COVID-19 is assessed only in non-hospitalized adults.
18 March 2022	Cardiovascular & thrombotic events were added as AESIs which are described as potential risks in the latest IB version. A Cardiovascular Event Adjudication Committee was added to provide an independent, external, systematic, and unbiased assessment of de-identified blinded data to systematically evaluate CV events.

Notes:

---

## **Interruptions (globally)**

Were there any global interruptions to the trial? No

## **Limitations and caveats**

None reported

---

## **Online references**

<http://www.ncbi.nlm.nih.gov/pubmed/36411267>

<http://www.ncbi.nlm.nih.gov/pubmed/35688164>